18 F-3-fluoro-5-[(pyridin-3-yl)ethynyl]benzonitrile ( 18 F-FPEB) is a potent and specific radioligand for the metabotropic glutamate receptor subtype 5 (mGluR5). Before undertaking clinical research studies with 18 F-FPEB, we performed studies of human radiation dosimetry. Methods: Serial whole-body scans were obtained in 9 healthy human subjects (5 men, 4 women) for 190-440 min after the intravenous administration of 18 F-FPEB. Radiation doses were estimated using the OLINDA/EXM software. Results: Peak organ doses were to the urinary bladder wall, 0.258 mGy/MBq (0.955 rad/mCi), and gallbladder wall, 0.193 mGy/MBq (0.716 rad/mCi). The effective dose was 0.025 mSv/MBq (0.0922 rem/mCi). The doses to the red marrow and spleen were 0.00797 mGy/MBq (0.0295 rad/mCi) and 0.00709 mGy/ MBq (0.0262 rad/mCi), respectively. Reducing the urinary voiding interval to 60 or 90 min lowered the urinary bladder wall dose to 0.0885 mGy/MBq (0.327 rad/mCi) or 0.128 mGy/MBq (0.473 rad/ mCi), respectively, and the effective dose to 0.0149 mSv/MBq (0.0551 rem/mCi) or 0.0171 mSv/MBq (0.0634 rem/mCi), respectively. Conclusion: Urinary voiding should be performed during 18 F-FPEB studies to minimize radiation exposure to research subjects.
The metabotropic glutamate receptor subtype 5 (mGluR5) is a type I metabotropic glutamatergic receptor, which is an important modulator of both N-methyl-D-aspartate and dopamine receptor signaling; it positively modulates N-methyl-D-aspartate receptor function and has complex interactions with dopamine receptor intracellular signaling (1, 2) . Altered function of the mGluR5 has been implicated in the pathophysiology of several neurologic and psychiatric disorders including Fragile X syndrome (3), Huntington and Parkinson disease (4, 5) , psychostimulant drug and alcohol abuse (6) (7) (8) , depression, and anxiety as well as being involved in learning and memory (9) (10) (11) (12) . 18 F-3-fluoro-5-[(pyridin-3-yl)ethynyl] benzonitrile ( 18 F-FPEB) is a promising radioligand for imaging the mGluR5 in humans. It has a high affinity (0.11-0.15 nM) for the mGluR5 and nearly optimal lipophilicity for imaging, with a logP of 2.8 (13) . Initial human imaging studies have shown high contrast between regions rich in mGluR5 levels, such as the anterior cingulated, and regions with low levels, such as the cerebellum and pons, as well as the ability to estimate regional receptor levels using both bolus administration with 2-tissue-compartment modeling and bolus-infusion administration (14, 15) . Given the importance of the mGluR5 in several disease states and its promise as a PET radioligand for studies of mGluR5, we undertook studies of human radiation dosimetry of 18 F-FPEB.
MATERIALS AND METHODS
After approval of this study by the appropriate institutional review boards (IRBs), all subjects provided written informed consent before enrollment. All subjects had to be 18 y or older and have a normal medical history, physical examination, and laboratory testing including a comprehensive metabolic panel, complete blood panel with differential, urine analysis, negative urine drug screens, and a normal electrocardiogram. A history of significant medical condition, psychiatric disorder including any history of drug abuse or eating disorder, pregnancy, and lactation were exclusion criteria. Nine healthy subjects (5 men and 4 women; mean age, 23.7 y; age range, 18-47 y) were studied after intravenous bolus administration of 18 . Seven of the 9 subjects were studied at Vanderbilt after approval by the Vanderbilt IRB using a Discovery DTSE PET/CT scanner (GE Healthcare) and were scanned for 190 min after administration of 18 F-FPEB. Serial whole-body images were obtained from the top of the head to the mid thigh. Two subjects were studied at the Institute for Neurodegenerative Disorders after approval from the New England IRB using an ECAT EXACT HR1 PET scanner (Siemens) and were scanned for 382 and 440 min after 18 F-FPEB administration using serial wholebody acquisitions from the top of the head to the mid thigh. For the calculation of radiation dosimetry, regions of interest were drawn around regions representing major organs at all time points with appropriate decay corrections. The resultant region-of-interest data were fit to timeactivity curves using the SAAM II software (SAAM Institute, University of Washington) (16) . Time-activity curves were integrated and timeactivity integrals entered into the OLINDA/EXM (Vanderbilt University) software (17, 18) ; organ dose estimates and effective dose values were obtained using the most appropriate anthropomorphic model for each subject. Urine excretion was modeled using the dynamic bladder model provided in the OLINDA/EXM code.
RESULTS
Organ residence times for 18 F-FPEB are shown in Table 1 . The calculated radiation dose estimates are shown in Table 2 . When urinary voiding at 3.5 h after 18 F-FPEB administration was used, the highest organ doses were to the urinary bladder wall (0.258 mGy/MBq [0.955 rad/mCi]) and the gallbladder wall (0.193 mGy/ MBq [0.716 rad/mCi]). The highest doses to blood-forming organs were to the red marrow (0.00797 mGy/MBq [0.0295 rads/mCi]) and spleen (0.00709 mGy/MBq [0.0262 rad/mCi]). The highest gonadal dose was to the ovaries (0.0185 mGy/MBq [0.0684 rad/ mCi]). The effective dose was 0.025 mSv/MBq (0.0922 rem/mCi). Reducing the urinary bladder voiding interval to 60 or 90 min produced significant decreases in the dose to the urinary bladder wall, lowering absorbed doses to 0.0885 mGy/MBq (0.327 rad/ mCi) for 1-h voiding and 0.128 mGy/MBq (0.473 rad/mCi) for 1.5-h voiding. Decreases were also seen in the effective dose, with reductions to 0.0149 mSv/MBq (0.0551 rem/mCi) for 1-h voiding and 0.0171 mSv/MBq (0.0634 rem/mCi) for 1.5-h voiding. Smaller decrements were seen in doses to the ovaries and red marrow, but the dose to the gallbladder wall was virtually unchanged.
DISCUSSION
The results of the current study indicate that multiple 185-MBq (5-mCi) doses of 18 F-FPEB can be administered for studies of cerebral mGluR5 in humans. To minimize the radiation dose received by human subjects, it is recommended that bladder voiding be done at 1 or 1.5 h after bolus administration of 18 F-FPEB, which significantly lowers both the urinary bladder wall and the effective doses. Previous studies indicate that 1.5 h of imaging after bolus injection of 18 F-FPEB should allow quantitation of mGluR5 levels in all brain regions; for such studies, urinary voiding at the end of the imaging study is recommended (14, 15) .
In comparing the present study with a recently published study of radiation dosimetry (14) , the greatest difference between the previous and the current radiation dosimetry studies is the dose to the urinary bladder wall, which is significantly higher in the current study. In the prior study, the dose to the urinary bladder wall was 0.047 mGy/MBq (0.18 rad/mCi) versus 0.258 mGy/MBq (0.955 rad/mCi) in the current study. The reason for this difference may be the longer duration of scanning in the current study than in the previous study, 190-440 versus 90 min. The greater urinary bladder wall dose also produces a somewhat higher effective dose than reported in the previous study-that is, 0.025 mGy/MBq (0.0922 rad/mCi) without voiding versus 0.017 mGy/MBq (0.062 rad/mCi). Voiding at 90 min reduces the effective dose to virtually the same dose reported in the prior study and decreases the urinary bladder wall dose by more than 50%. With urinary voiding intervals of 1.0 or 1.5 h, the highest organ dose becomes the gallbladder wall, 0.193 mGy/MBq (0.714 rad/mCi), which is remarkably similar to the dose reported by Wong et al. (14) , 0.19 mGy/MBq (0.71 rad/mCi).
CONCLUSION
The results of the current study demonstrate that 18 F-FPEB can be administered in doses to humans sufficient to allow quantitation of regional mGluR5 levels in brain. To minimize absorbed radiation doses, urinary voiding at 1 to 1.5 h is advocated to achieve the minimum reasonable dose, particularly for the urinary bladder wall and the effective dose.
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